

BIOLASE TECHNOLOGY INC
Form 8-K
May 05, 2011

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2011

BIOLASE TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other Jurisdiction of Incorporation)	000-19627 (Commission File Number)	87-0442441 (IRS Employer Identification No.)
--	--	--

4 Cromwell Irvine, California (Address of Principal Executive Offices)	92618 (Zip Code)
--	----------------------------

Registrant's telephone number, including area code: **(949) 361-1200**

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Biolase Technology, Inc. (the “Company”) expects to make a slide presentation at its annual meeting of stockholders, scheduled to be held on May 5, 2011. A copy of the Company’s slide presentation is furnished herewith as Exhibit 99.1.

The information contained in this current report on Form 8-K and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibit to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Slide Presentation for the Annual Meeting of Stockholders to be held on May 5, 2011.

2

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOLASE TECHNOLOGY, INC.

Date: May 5, 2011

By: /s/ Federico Pignatelli

Federico Pignatelli

Chairman and Chief Executive Officer

3

3

Exhibit Index

Exhibit No.	Description
99.1	Slide Presentation for the Annual Meeting of Stockholders to be held on May 5, 2011.
	4
	4